Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia

Pneumonia Clinical Trial

Official title:

Amoxicillin Versus Benzyl Penicillin for Severe Childhood Pneumonia Amongst Inpatients: An Open Label Randomised Controlled Non-inferiority Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01399723
• Other study ID #: KEMRI_CT_2010/0014
• Secondary ID: SSC 1911
• Status: Completed
• Phase: Phase 3
• First received: July 12, 2011
• Last updated: January 28, 2015
• Start date: September 2011
• Est. completion date: September 2013

Study information

• Verified date: January 2015
• Source: KEMRI-Wellcome Trust Collaborative Research Program
• Contact: n/a
• Is FDA regulated: No
• Health authority: Kenya: Pharmacy and Poisons Board
• Study type: Interventional

Clinical Trial Summary

This study seeks to determine whether clinical outcome following initial treatment of severe pneumonia with oral amoxicillin is as effective as the current standard benzyl penicillin. The study will also provide an estimate of the proportion of Kenyan children with severe pneumonia who fail treatment with a single antibiotic.

Description:

Case management for the treatment of childhood acute respiratory infections has been widely promoted in many developing countries for over 20 years. Despite this, pneumonia continues to claim over 1.5 million lives of children under five annually. The use of affordable, easily-administered, safe, effective treatments can potentially reduce the burden of childhood pneumonia. The WHO recommends the use of a single antibiotic for the treatment of severe pneumonia. Whereas in Asia, evidence from large randomized clinical trials has changed policy recommendations for treatment of severe pneumonia from parenteral penicillin to oral amoxicillin, there is little evidence to inform a similar move in African children where pneumonia is associated with poorer outcomes. In this study the investigators will investigate effectiveness of oral amoxicillin versus the current standard treatment, benzyl penicillin in severe childhood pneumonia using a randomized controlled non-inferiority design preceded by a pilot pre-intervention phase. The investigators will also collect observational data HIV-exposed / infected children with severe pneumonia. 594 children aged 2 - 59 months admitted with clinical signs of severe pneumonia to up to 7 hospitals in Kenya will be randomly assigned to receive either oral amoxicillin or injectable benzyl penicillin. They will then be followed up for the primary outcome of pre-defined treatment failure at 48 hours. The results of this trial will provide valuable data on the effectiveness of oral amoxicillin in the treatment of severe pneumonia in a population of Kenyan children and determine the practicability of conducting large pragmatic trials on pneumonia in Africa similar to those done in Asia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 561
• Est. completion date: September 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Months to 59 Months

Eligibility

Inclusion Criteria:

• Clinical signs of WHO-defined severe pneumonia

• Age 2 months to 59 months

Exclusion Criteria:

• Clinical signs of WHO-defined very severe pneumonia

• Clinical or laboratory diagnosis of meningitis

• Clinical diagnosis of severe malnutrition (marasmus/kwashiorkor)

• Clinical or laboratory diagnosis of severe anaemia requiring transfusion

• HIV-exposure on rapid HIV antibody test (only observational data will be collected from these patients)

• Elimination of signs of severe pneumonia in a child with wheeze after outpatient bronchodilator therapy

• Chronic condition that may underlie or contribute to a presentation with respiratory distress such as: known chronic renal or cardiac disease, presence of cerebral palsy predisposing child to aspiration/hypostatic pneumonia

• Established bronchiectasis or congenital abnormality of the lower respiratory tract

• Upper airway obstruction producing stridor

• Admission from outpatient clinic specifically for treatment of TB

• Referral from another inpatient facility following treatment with injectable antibiotics for more than 24 hours or because the initial regimen is considered to have failed

• Documented history of >48hours treatment with oral amoxicillin

• Failure to obtain informed consent

• Penicillin allergy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pneumonia

Intervention

Drug:
• Amoxicillin
Oral 45mg/kg 12 hourly
• Benzyl penicillin
Intravenous 50,000IU/kg 6 hourly

Locations

Country	Name	City	State
Kenya	Bungoma District Hospital	Bungoma	Western
Kenya	Embu Provincial General Hospital	Embu	Eastern
Kenya	Kerugoya District Hospital	Kerugoya	Central
Kenya	Kisumu East District Hospital	Kisumu	Nyanza
Kenya	New Nyanza Provincial General Hospital	Kisumu	Nyanza
Kenya	Mbagathi District Hospital	Nairobi

Sponsors (4)

Lead Sponsor	Collaborator
KEMRI-Wellcome Trust Collaborative Research Program	London School of Hygiene and Tropical Medicine, University of Nairobi, University of Oxford

Country where clinical trial is conducted

Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment Failure at 48 Hours (Two Full Days After Enrollment)	Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 <85% or <80% for altitude < or =1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature =38?C Respiratory rate =5bpm of admission rate if above age-adjusted normal upper limit	48 hours	No
Secondary	Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First)	Treatment failure as defined in the primary outcome measure.	Patients will be followed up from the day of hospitalisation (day 0) until the day of medical discharge (average duration of 3 days) or until day 5 of hospitalisation (whichever occurs first).	No
Secondary	Readmission With Diagnosis of Severe or Very Severe Pneumonia Within 14 Days of Enrollment		Day 0 to Day 14	No
Secondary	Death at or Before Five Days Following Enrollment	Death defined as: in-hospital death occurring at any time after randomisation (recruitment for HIV-exposed participants) or verbal report of death of the enrolled patient from parent/guardian communicated either directly or via telephone conversation.	Day 0 to Day 5	No
Secondary	Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview	Definition of death as described in third secondary outcome measure.	Day 14	No